NASDAQ:AEMD Aethlon Medical (AEMD) Stock Price, News & Analysis $2.02 -0.08 (-3.57%) As of 01:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aethlon Medical Stock (NASDAQ:AEMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aethlon Medical alerts:Sign Up Key Stats Today's Range$2.05▼$2.2550-Day Range$1.65▼$2.3952-Week Range$1.36▼$34.05Volume682,724 shsAverage Volume57,503 shsMarket Capitalization$3.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings. The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts. Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.AI Generated. May Contain Errors. Read More Aethlon Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreAEMD MarketRank™: Aethlon Medical scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingAethlon Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAethlon Medical has only been the subject of 1 research reports in the past 90 days.Read more about Aethlon Medical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aethlon Medical are expected to grow in the coming year, from ($9.94) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aethlon Medical is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aethlon Medical is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAethlon Medical has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aethlon Medical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.90% of the float of Aethlon Medical has been sold short.Short Interest Ratio / Days to CoverAethlon Medical has a short interest ratio ("days to cover") of 1.14, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aethlon Medical has recently decreased by 59.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAethlon Medical does not currently pay a dividend.Dividend GrowthAethlon Medical does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.43 News SentimentAethlon Medical has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aethlon Medical this week, compared to 3 articles on an average week.Search Interest6 people have searched for AEMD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aethlon Medical insiders have not sold or bought any company stock.Percentage Held by Insiders0.71% of the stock of Aethlon Medical is held by insiders.Percentage Held by Institutions1.99% of the stock of Aethlon Medical is held by institutions.Read more about Aethlon Medical's insider trading history. Receive AEMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AEMD Stock News HeadlinesAEMD: Hitting key milestones as company advances clinical studyMarch 24, 2026 | msn.comAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB ReviewMarch 24, 2026 | prnewswire.comAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $500 into a fortune while the average stock lost 90% of its value. His son Martin later digitized those same formulas into Weiss Ratings, a system now tracking 22,000 stocks with 1.2 billion daily calculations. That system called the bank failures of the 1980s, the dot-com bust, 2008, and the 2020 crash. Right now it is flashing Code Red - issuing Must-Sell warnings on 10 widely held US stocks and upgrading 3 under-the-radar names to an urgent Buy. Access the full briefing at 79% off during the Memorial Day Savings Event.May 18 at 1:00 AM | Weiss Ratings (Ad)OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCRMarch 20, 2026 | msn.comAEMD: Positive Takeaways From CEO ChatMarch 19, 2026 | finance.yahoo.comAethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying EquityMarch 17, 2026 | tipranks.comAethlon Medical Engages Maxim Group LLC to Evaluate Strategic OpportunitiesMarch 12, 2026 | prnewswire.comAethlon Medical to Present at the Life Sciences Investor Forum on March 12thMarch 6, 2026 | financialpost.comFSee More Headlines AEMD Stock Analysis - Frequently Asked Questions How have AEMD shares performed this year? Aethlon Medical's stock was trading at $2.77 at the beginning of 2026. Since then, AEMD stock has decreased by 23.1% and is now trading at $2.13. How were Aethlon Medical's earnings last quarter? Aethlon Medical, Inc. (NASDAQ:AEMD) released its quarterly earnings data on Thursday, February, 12th. The medical equipment provider reported ($2.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.01) by $0.44. Read the conference call transcript. When did Aethlon Medical's stock split? Aethlon Medical shares reverse split on Thursday, October 5th 2023.The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Aethlon Medical? Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aethlon Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aethlon Medical investors own include Advanced Micro Devices (AMD), Nokia (NOK), NVIDIA (NVDA), Pfizer (PFE), Plug Power (PLUG), Organigram Global (OGI). Company Calendar Last Earnings2/12/2026Today5/18/2026Next Earnings (Estimated)6/25/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AEMD's financial health is in the Red zone, according to TradeSmith. AEMD has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - HMO Sub-IndustryMedical Equipment Current SymbolNASDAQ:AEMD CIK882291 Webwww.aethlonmedical.com Phone(858) 459-7800FaxN/AEmployees10Year Founded1998Profitability EPS (Trailing Twelve Months)($14.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-219.39% Return on Assets-164.33% Debt Debt-to-Equity RatioN/A Current Ratio5.68 Quick Ratio5.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.52 per share Price / Book0.08Miscellaneous Outstanding Shares1,570,000Free Float1,558,000Market Cap$3.18 million OptionableNo Data Beta1.50 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AEMD) was last updated on 5/18/2026 by MarketBeat.com Staff. From Our PartnersMusk’s warning just revealed a $1T opportunityElon Musk recently warned that AI could force governments to introduce universal income. Mode Mobile isn't wai...Mode Mobile | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredThe smartest SpaceX play before Memorial DayWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayI spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...Decentralized Masters | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aethlon Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
